학술논문
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Document Type
article
Author
Ngai, Lok; Ma, Connie; Maguire, Orla; Do, An; Robert, Alberto; Logan, Aaron; Griffiths, Elizabeth; Nemeth, Michael; Green, Cherie; Pourmohamad, Tony; van Kuijk, Bo; Snel, Alexander; Kwidama, Zinia; Venniker-Punt, Bianca; Cooper, James; Manz, Markus; Gjertsen, Bjørn; Smit, Linda; Ossenkoppele, Gert; Janssen, Jeroen; Cloos, Jacqueline; Sumiyoshi, Teiko
Source
European Journal of Haematology. 107(3)
Subject
Language
Abstract
OBJECTIVES: This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1 bimodal associations with leukemia and patient-specific characteristics. METHODS: Flow cytometry assays were performed to assess the deeper immunophenotyping of CLL-1 bimodality. Cytogenetic analysis was performed to characterize the gene mutation on CLL-1-negative subpopulation of CLL-1 bimodal AML samples. RESULTS: The frequency of a bimodal pattern of CLL-1 expression of CD34+ blasts ranged from 8% to 65% in the different cohorts. Bimodal CLL-1 expression was most prevalent in patients with MDS-related AML (P = .011), ELN adverse risk (P = .002), NPM1 wild type (WT, P = .049), FLT3 WT (P = .035), and relatively low percentages of leukemia-associated immunophenotypes (P = .006). Additional immunophenotyping analysis revealed the CLL-1- subpopulation may consist of pre-B cells, immature myeloblasts, and hematopoietic stem cells. Furthermore, (pre)-leukemic mutations were detected in both CLL-1+ and CLL-1- subfractions of bimodal samples (N = 3). CONCLUSIONS: C-lectin-like molecule 1 bimodality occurs in about 25% of AML patients and the CLL-1- cell population still contains malignant cells, hence it may potentially limit the effectiveness of CLL-1-targeted therapies and warrant further investigation.